Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 8
What semaglutide actually costs in the UK
NHS patients may pay £9.90 per item in England, while NICE lists Wegovy packs at £73.25 to £175.80 before a confidential NHS discount.
Semaglutide UK status: what changed
Semaglutide remains prescription-only in the UK, with 2026 changes to Wegovy doses, tablets, liver-disease use and product safety information.
Can you import Semax into the UK?
Great Britain exempts household medicine imports from one licence rule, but that does not approve Semax, validate a seller or guarantee parcel release.
What Semax actually costs in the UK
Zero official UK Semax prices were found. MHRA and EMA checks identified no authorised pack to price, and vendor listings are excluded.
Antidiabetic Drug Evidence in 2026
A 2026 pharmacology review maps modern diabetes drugs, while primary outcome trials show why class summaries cannot substitute for medicine-specific results.
Mental Health After Two Obesity Treatments
A six-month cohort compared psychological outcomes after bariatric surgery and incretin therapy, including tirzepatide and semaglutide.
GLP-1 Cardiovascular Effects Over Time
A 10-trial network meta-analysis supported a class-level MACE reduction, but time-varying regimen estimates were imprecise and assumption-dependent.
Food-Derived Peptides in Obese Rodents
NDP-35 and NDP-45 changed satiety hormones and body weight in rodent models, but no human trial has established efficacy or safety.
Semaglutide for Secondary CV Prevention
SELECT found a 1.5-point absolute difference in major cardiovascular events, while a 2026 NICE appraisal addresses the separate NHS access question.
Semaglutide and Ventricular Extrasystoles
A two-database safety analysis found disproportionate reporting of ventricular extrasystoles with semaglutide, but it cannot prove causation.
Tirzepatide and Lipoedema Symptoms
A 49-woman clinic cohort found symptom improvement did not track with weight loss, but no control group means the drug effect remains uncertain.
Obesity Drug Endpoints in Breast Cancer
A 2026 review argues weight and BMI alone cannot describe treatment effects during endocrine therapy for HR-positive early breast cancer.